Literature DB >> 17188878

A simple, yet highly accurate, QSAR model captures the complement inhibitory activity of compstatin.

Chandrika Mulakala1, John D Lambris, Yiannis Kaznessis.   

Abstract

Compstatin is a 13-residue cyclic peptide inhibitor of complement activation that was originally identified through phage-mediated presentation of a peptide library to C3b. Recent efforts to improve its activity have led to a rich dataset of complement analogs, with the most active analog being approximately 260 times more active than the parent compstatin. In the present work, a highly transparent quantitative structure-activity relationship model (Radj2=0.89) with four parameters is presented that captures important physico-chemical and geometrical properties of the analog molecules with regard to activity. The number of aromatic bonds and hydrophobicity of the fourth residue of compstatin correlated strongly with activity. Also important were the hydrophobic patch size near the disulfide bond and the solvent-accessible surface area occupied by nitrogen atoms of basic amino acid residues.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17188878      PMCID: PMC1995432          DOI: 10.1016/j.bmc.2006.12.015

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  18 in total

1.  Studies of structure-activity relations of complement inhibitor compstatin.

Authors:  Athena M Soulika; Dimitrios Morikis; Maria-Rosa Sarrias; Melinda Roy; Lynn A Spruce; Arvind Sahu; John D Lambris
Journal:  J Immunol       Date:  2003-08-15       Impact factor: 5.422

2.  Complement depletion improves neurological function in cerebral ischemia.

Authors:  U S Vasthare; F C Barone; H M Sarau; R H Rosenwasser; M DiMartino; W F Young; R F Tuma
Journal:  Brain Res Bull       Date:  1998       Impact factor: 4.077

3.  Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.

Authors:  A Sahu; B K Kay; J D Lambris
Journal:  J Immunol       Date:  1996-07-15       Impact factor: 5.422

4.  The structural basis of compstatin activity examined by structure-function-based design of peptide analogs and NMR.

Authors:  Dimitrios Morikis; Melinda Roy; Arvind Sahu; Anastasios Troganis; Patricia A Jennings; George C Tsokos; John D Lambris
Journal:  J Biol Chem       Date:  2002-02-14       Impact factor: 5.157

Review 5.  The complement system in myocardial ischaemia/reperfusion injury.

Authors:  K S Kilgore; G S Friedrichs; J W Homeister; B R Lucchesi
Journal:  Cardiovasc Res       Date:  1994-04       Impact factor: 10.787

6.  Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons.

Authors:  A M Soulika; M M Khan; T Hattori; F W Bowen; B A Richardson; C E Hack; A Sahu; L H Edmunds; J D Lambris
Journal:  Clin Immunol       Date:  2000-09       Impact factor: 3.969

7.  Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin.

Authors:  A Sahu; A M Soulika; D Morikis; L Spruce; W T Moore; J D Lambris
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

8.  Complement activation by beta-amyloid in Alzheimer disease.

Authors:  J Rogers; N R Cooper; S Webster; J Schultz; P L McGeer; S D Styren; W H Civin; L Brachova; B Bradt; P Ward
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

9.  Improvement of the anti-C3 activity of compstatin using rational and combinatorial approaches.

Authors:  D Morikis; A M Soulika; B Mallik; J L Klepeis; C A Floudas; J D Lambris
Journal:  Biochem Soc Trans       Date:  2004-02       Impact factor: 5.407

Review 10.  Therapeutic uses of recombinant complement protein inhibitors.

Authors:  K R Kalli; P Hsu; D T Fearon
Journal:  Springer Semin Immunopathol       Date:  1994
View more
  5 in total

Review 1.  Compstatin: a complement inhibitor on its way to clinical application.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

2.  Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency.

Authors:  Hongchang Qu; Paola Magotti; Daniel Ricklin; Emilia L Wu; Ioannis Kourtzelis; You-Qiang Wu; Yiannis N Kaznessis; John D Lambris
Journal:  Mol Immunol       Date:  2010-11-09       Impact factor: 4.407

3.  Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin.

Authors:  Paola Magotti; Daniel Ricklin; Hongchang Qu; You-Qiang Wu; Yiannis N Kaznessis; John D Lambris
Journal:  J Mol Recognit       Date:  2009 Nov-Dec       Impact factor: 2.137

4.  Development of a new pharmacophore model that discriminates active compstatin analogs.

Authors:  Ting-Lan Chiu; Chandrika Mulakala; John D Lambris; Yiannis N Kaznessis
Journal:  Chem Biol Drug Des       Date:  2008-10       Impact factor: 2.817

Review 5.  Multiscale models of the antimicrobial peptide protegrin-1 on gram-negative bacteria membranes.

Authors:  Dan S Bolintineanu; Victor Vivcharuk; Yiannis N Kaznessis
Journal:  Int J Mol Sci       Date:  2012-09-05       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.